About Receptos, a wholly-owned subsidiary of celgene
Receptos, a wholly-owned subsidiary of Celgene: A Leader in Biopharmaceutical Innovation
Bristol Myers Squibb is a global biopharmaceutical company that has been committed to discovering, developing and delivering innovative medicines to patients with serious diseases for over 130 years. One of its subsidiaries, Receptos, is a leader in the field of biopharmaceutical innovation.
Receptos was founded in 2008 with the goal of developing new treatments for immune and metabolic disorders. The company's focus on these areas has led to the development of several groundbreaking therapies that have helped improve the lives of millions of people around the world.
One such therapy is Ozanimod, which was developed by Receptos as a treatment for multiple sclerosis (MS). MS is a chronic autoimmune disease that affects more than 2.5 million people worldwide. Ozanimod works by modulating immune cell migration into the central nervous system (CNS), which helps reduce inflammation and prevent damage to nerve cells.
Another therapy developed by Receptos is RPC1063, which targets S1P1 receptors in lymphocytes and reduces their ability to migrate from lymph nodes into circulation. This therapy has shown promise as a treatment for ulcerative colitis (UC) and Crohn's disease (CD), two chronic inflammatory bowel diseases that affect millions of people worldwide.
In addition to its work on immune and metabolic disorders, Receptos also focuses on developing therapies for other serious diseases such as cancer. The company's pipeline includes several promising oncology drugs that are currently undergoing clinical trials.
One such drug is CC-122, an oral inhibitor of cereblon E3 ligase complex activity being studied in hematological malignancies including diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Another drug under development at Receptos is CC-220, an oral immunomodulatory compound being studied in hematological malignancies including MM.
Receptos' commitment to innovation extends beyond its research efforts. The company also invests heavily in technology platforms that enable it to develop new therapies more efficiently and effectively than ever before. These platforms include advanced computational modeling tools, high-throughput screening technologies, and state-of-the-art laboratory facilities staffed by some of the brightest minds in biopharmaceutical research today.
Overall, Receptos represents one of Bristol Myers Squibb's most promising subsidiaries when it comes to developing innovative treatments for serious diseases like MS, UC/CD or cancer. With its focus on cutting-edge science combined with state-of-the-art technology platforms staffed by top-notch researchers from around the world - there can be no doubt about this subsidiary’s potential impact on healthcare industry!